March 23, 2010 - a new experimental drug can alleviate menstrual pain caused by the coverage, rather a symptom than pain.
Researchers say that drugs are now the second phase of clinical trials in Britain and the United States, works by blocking the hormone vasopressin, which participates in reducing cancer. Increased levels of this hormone are considered to cause the pain associated with menstrual pain.
Menstrual pain, known in medical terms as dysmenorrhea, affect over 50% of women of childbearing age. They arise when the smooth muscles of the uterus contract with increasing frequency. The most common symptoms of typhoid and press back, dysmenorrhea, but may also cause nausea, vomiting, sweating and dizziness.
Treatments for dysmenorrhea include painkillers, anti-inflammatory drugs and contraceptives that stop menstruation. But researchers say that the only help symptoms than the cause, and may have undesirable side effects.
"We hope that the drug will provide a more effective treatment option for millions of women around the world with this painful condition," researcher Andrzej R. Batt with Vantia Ltd., a British pharmaceutical company that develops and checks for drugs, according to a press release. "Dysmenorrhea is not only lowers the quality of life for millions of women, but hidden in the scale of the whole society, the economic cost includes a great number of days lost from work and school.
Batt presented new information on the molecular structure of the drug, known as VA111913, today at the annual meeting of the American Chemical Society in San Francisco.
Last year, the drug was the first phase of clinical trials showing it was safe for further human studies. Drugs were changed to allow it to be considered as a pill rather than an injection.
Phase II clinical trials conducted at sites in Britain and the United States, which evaluate the effectiveness of the drug in women with dysmenorrhea.
Results of Phase II clinical trial, expected to be released later this year. If these results confirm the initial findings and phase III clinical trial results to be positive, the drug may be FDA approved and available for use for about four years.
среда, 24 марта 2010 г.
вторник, 23 марта 2010 г.
Insurance and pharmaceutical companies can weather the reforms, but some of them regard
Health insurance and pharmaceutical industry can ride out the historic health reform is better than one might expect.
Although the pharmaceutical industry to prevent the control of prices and tougher federal regulations, insurance embraced greater access to health care for uninsured Americans - but still concerned about how the country will pay for it.
Even Wall Street cheered the prospects of this law with pharmaceutical companies pulling the market higher yesterday.
"Although the bill passed by the House is far from perfect, this coverage will give millions of Americans access to essential medical services and medicines," Merck said in a manual prepared statement.
Insurance sector was more mixed in the new law. Insurers believe that this bill will not be less than the increasing health care costs and improve patient care. Most alarming to them is their belief that expanding access to health care to millions of uninsured - half of which they plan to stay on Medicaid - will increase costs for all others.
"Laws, increase taxes on insurers, which are not increasing evidence of care and service transparency of price and quality rather than improving the quality of care of American families will receive," said William J. Marino, chairman and chief executive officer of Horizon Blue Cross Blue Shield New Jersey's largest state health insurer, in prepared statement.
Manufacturers of drugs, many of which have large operations in New Jersey stand to billions of dollars, as previously uninsured consumers are starting to go on doctors and prescription drugs. They also won several advantages over his rival of common drugs. One of its provisions, for example, eliminates the so-called Medicare "bagel hole, requiring senior citizens to pay for their own medicines after a certain period of time. As a result, many decided to buy cheap generic versions or they stopped the drug altogether.
Another provision gives drugmakers for 12 years to sell biological products - expensive new treatments of human proteins and cells - before they face a common competition.
Uwe Reinhardt, Health Economist at Princeton University, said the industry has received "very good deal.''
Tony Butler, an analyst with Barclays Capital, which monitors the pharmaceutical industry, says, except for closing the so-called "bagel dyra''v prescription drug coverage Medicare, nothing will benefit drug manufacturers directly.
"Drug trafficking done better than it would if you re-import or price controls or some other evil things that were around vyry DC did it in the legislation,''said Butler." This point of drug made better because of what medical care is not included.''
For health insurers, potential customers will be overshadowed by the growth reduction of subsidies for individual Medicare Advantage plans offered for the elderly, as well as prospects for the new rules. Industry, through its trade group America's Health Insurance Plans, said the legislation will not control costs and that people still will wait until they are sick to buy coverage.
"Medikeyd reimbursement of medical workers is much lower than private environment. To the extent hospitals get more clients seeking help, it will transfer costs, which passes through the private sector," said Dave Guilmette, president of the national segment of the alert, which provides health insurance 500000 people in New Jersey through employer self-insurance plans.
"The main challenge we hear from our customers in New Jersey that the health of Premium tax levies that are imposed on pharmaceutical companies and manufacturers of medical equipment will be transferred with them," said Guilmette.
Over the next decade, pharmaceutical companies have to pay a $ 85 billion industry in the form of allowances and lower prices they receive from government programs. To pay for higher costs for patients with more medical needs, managed care providers need a large number of young, healthy people in the pool "to help spread the costs more effectively," said Paul H. Keckley, executive director of Deloitte Center for Health 'I Solutions, based in Washington, DC, research firm.
For this reason, "consolidation in the insurance industry looks inevitable," he said.
Although the pharmaceutical industry to prevent the control of prices and tougher federal regulations, insurance embraced greater access to health care for uninsured Americans - but still concerned about how the country will pay for it.
Even Wall Street cheered the prospects of this law with pharmaceutical companies pulling the market higher yesterday.
"Although the bill passed by the House is far from perfect, this coverage will give millions of Americans access to essential medical services and medicines," Merck said in a manual prepared statement.
Insurance sector was more mixed in the new law. Insurers believe that this bill will not be less than the increasing health care costs and improve patient care. Most alarming to them is their belief that expanding access to health care to millions of uninsured - half of which they plan to stay on Medicaid - will increase costs for all others.
"Laws, increase taxes on insurers, which are not increasing evidence of care and service transparency of price and quality rather than improving the quality of care of American families will receive," said William J. Marino, chairman and chief executive officer of Horizon Blue Cross Blue Shield New Jersey's largest state health insurer, in prepared statement.
Manufacturers of drugs, many of which have large operations in New Jersey stand to billions of dollars, as previously uninsured consumers are starting to go on doctors and prescription drugs. They also won several advantages over his rival of common drugs. One of its provisions, for example, eliminates the so-called Medicare "bagel hole, requiring senior citizens to pay for their own medicines after a certain period of time. As a result, many decided to buy cheap generic versions or they stopped the drug altogether.
Another provision gives drugmakers for 12 years to sell biological products - expensive new treatments of human proteins and cells - before they face a common competition.
Uwe Reinhardt, Health Economist at Princeton University, said the industry has received "very good deal.''
Tony Butler, an analyst with Barclays Capital, which monitors the pharmaceutical industry, says, except for closing the so-called "bagel dyra''v prescription drug coverage Medicare, nothing will benefit drug manufacturers directly.
"Drug trafficking done better than it would if you re-import or price controls or some other evil things that were around vyry DC did it in the legislation,''said Butler." This point of drug made better because of what medical care is not included.''
For health insurers, potential customers will be overshadowed by the growth reduction of subsidies for individual Medicare Advantage plans offered for the elderly, as well as prospects for the new rules. Industry, through its trade group America's Health Insurance Plans, said the legislation will not control costs and that people still will wait until they are sick to buy coverage.
"Medikeyd reimbursement of medical workers is much lower than private environment. To the extent hospitals get more clients seeking help, it will transfer costs, which passes through the private sector," said Dave Guilmette, president of the national segment of the alert, which provides health insurance 500000 people in New Jersey through employer self-insurance plans.
"The main challenge we hear from our customers in New Jersey that the health of Premium tax levies that are imposed on pharmaceutical companies and manufacturers of medical equipment will be transferred with them," said Guilmette.
Over the next decade, pharmaceutical companies have to pay a $ 85 billion industry in the form of allowances and lower prices they receive from government programs. To pay for higher costs for patients with more medical needs, managed care providers need a large number of young, healthy people in the pool "to help spread the costs more effectively," said Paul H. Keckley, executive director of Deloitte Center for Health 'I Solutions, based in Washington, DC, research firm.
For this reason, "consolidation in the insurance industry looks inevitable," he said.
среда, 17 марта 2010 г.
Obesity drug market tipped to slow
Low efficiency and negative side effects have an adverse effect on the sale and development of drugs against obesity, according to a forecast by Datamonitor.
Click here! Quantcast
The analyst firm business argued that professionals in health care always regarded obesity as the result of lifestyle choices that could be better managed through diet and exercise rather than drugs.
The market situation of weight loss was also hampered by the revelations of side effects caused by major players, Datamonitor said.
Drug sibutramine weight loss - marketed in Australia as Ectiva or Reductil - was suspended across the European Union in January after regulators deemed it caused increased risk of cardiovascular events.
"The sector continues to be plagued by low efficiency, the profiles of side effects and lack of reimbursement by providers of health care," chief analyst of health care at Datamonitor, Dr Nick Karachalias said .
"There is a certain irony that obesity as a major driver of type 2 diabetes growth of the pharmaceutical market, will not be processed on a large scale by the pharmaceutical market. Diets and industry personnel fitness are just too big. "
However, Datamonitor predicts that the market for drugs to manage diabetes could double in the next ten years, with the dipeptidyl peptidase IV (DPP-IV) inhibitors and glucagon-like-1 (GLP-1) agonists winners.
"Having benefited from a significant period of time that the DPP-IV only in the market, Januvia (sitagliptin) continue to be the market leader, despite having little clinical differentiation from other molecules in the classroom," Dr. Karachalias said.
Click here! Quantcast
The analyst firm business argued that professionals in health care always regarded obesity as the result of lifestyle choices that could be better managed through diet and exercise rather than drugs.
The market situation of weight loss was also hampered by the revelations of side effects caused by major players, Datamonitor said.
Drug sibutramine weight loss - marketed in Australia as Ectiva or Reductil - was suspended across the European Union in January after regulators deemed it caused increased risk of cardiovascular events.
"The sector continues to be plagued by low efficiency, the profiles of side effects and lack of reimbursement by providers of health care," chief analyst of health care at Datamonitor, Dr Nick Karachalias said .
"There is a certain irony that obesity as a major driver of type 2 diabetes growth of the pharmaceutical market, will not be processed on a large scale by the pharmaceutical market. Diets and industry personnel fitness are just too big. "
However, Datamonitor predicts that the market for drugs to manage diabetes could double in the next ten years, with the dipeptidyl peptidase IV (DPP-IV) inhibitors and glucagon-like-1 (GLP-1) agonists winners.
"Having benefited from a significant period of time that the DPP-IV only in the market, Januvia (sitagliptin) continue to be the market leader, despite having little clinical differentiation from other molecules in the classroom," Dr. Karachalias said.
Подписаться на:
Сообщения (Atom)